Natural Killer Cells in Cancer Immunotherapy

被引：121

作者：

Miller, Jeffrey S. ^{[1
]}

Lanier, Lewis L. ^{[2
,3
]}

机构：

[1] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA

[2] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA

[3] Parker Inst Canc Immunotherapy, San Francisco, CA 94143 USA

来源：

ANNUAL REVIEW OF CANCER BIOLOGY, VOL 3 | 2019年 / 3卷

关键词：

natural killer cell; immunotherapy; inhibitory receptor; IL-15; IL-2; REFRACTORY HODGKINS-DISEASE; ACUTE MYELOID-LEUKEMIA; INNATE LYMPHOID-CELLS; BISPECIFIC MONOCLONAL-ANTIBODIES; IFN-GAMMA PRODUCTION; ACTIVATES NK CELLS; CHAIN FV ANTIBODY; IN-VIVO EXPANSION; CD19 X CD3; T-CELLS;

D O I：

10.1146/annurev-cancerbio-030518-055653

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Natural killer (NK) cells have evolved to complement T and B cells in host defense against pathogens and cancer. They recognize infected cells and tumors using a sophisticated array of activating, costimulatory, and inhibitory receptors that are expressed onNKcell subsets to create extensive functional diversity. NKcells can be targeted to kill with exquisite antigen specificity by antibody-dependent cellular cytotoxicity. NK and T cells share many of the costimulatory and inhibitory receptors that are currently under evaluation in the clinic for cancer immunotherapy. As with T cells, genetic engineering is being employed to modify NK cells to specifically target them to tumors and to enhance their effector functions. As the selective pressures exerted by immunotherapies to augment CD8 + T cell responses may result in loss of MHC class I, NK cells may provide an important fail-safe to eliminate these tumors by their capacity to eliminate tumors that are "missing self."

引用

页码：77 / 103

页数：27

共 206 条

[1] Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial [J].

Arai, S. ;

Meagher, R. ;

Swearingen, M. ;

Myint, H. ;

Rich, E. ;

Martinson, J. ;

Klingemann, H. .

CYTOTHERAPY, 2008, 10 (06) :625-632

[2] A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors [J].

Arndt, MAE ;

Krauss, J ;

Kipriyanov, SM ;

Pfreundschuh, M ;

Little, M .

BLOOD, 1999, 94 (08) :2562-2568

[3] Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein [J].

Bachanova, Veronika ;

Cooley, Sarah ;

Defor, Todd E. ;

Verneris, Michael R. ;

Zhang, Bin ;

McKenna, David H. ;

Curtsinger, Julie ;

Panoskaltsis-Mortari, Angela ;

Lewis, Dixie ;

Hippen, Keli ;

McGlave, Philip ;

Weisdorf, Daniel J. ;

Blazar, Bruce R. ;

Miller, Jeffrey S. .

BLOOD, 2014, 123 (25) :3855-3863

[4] Allogeneic natural killer cells for refractory lymphoma [J].

Bachanova, Veronika ;

Burns, Linda J. ;

McKenna, David H. ;

Curtsinger, Julie ;

Panoskaltsis-Mortari, Angela ;

Lindgren, Bruce R. ;

Cooley, Sarah ;

Weisdorf, Daniel ;

Miller, Jeffrey S. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (11) :1739-1744

[5] CHARACTERIZATION OF THE LYMPHOCYTE-ACTIVATION GENE 3-ENCODED PROTEIN - A NEW LIGAND FOR HUMAN-LEUKOCYTE ANTIGEN CLASS-II ANTIGENS [J].

BAIXERAS, E ;

HUARD, B ;

MIOSSEC, C ;

JITSUKAWA, S ;

MARTIN, M ;

HERCEND, T ;

AUFFRAY, C ;

TRIEBEL, F ;

PIATIERTONNEAU, D .

JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (02) :327-337

[6] PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma [J].

Beldi-Ferchiou, Asma ;

Lambert, Marion ;

Dogniaux, Stephanie ;

Vely, Frederic ;

Vivier, Eric ;

Olive, Daniel ;

Dupuy, Stephanie ;

Levasseur, Frank ;

Zucman, David ;

Lebbe, Celeste ;

Sene, Damien ;

Hivroz, Claire ;

Caillat-Zucman, Sophie .

ONCOTARGET, 2016, 7 (45) :72961-72977

[7] A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma [J].

Benson, Don M., Jr. ;

Cohen, Adam D. ;

Jagannath, Sundar ;

Munshi, Nikhil C. ;

Spitzer, Gary ;

Hofmeister, Craig C. ;

Efebera, Yvonne A. ;

Andre, Pascale ;

Zerbib, Robert ;

Caligiuri, Michael A. .

CLINICAL CANCER RESEARCH, 2015, 21 (18) :4055-4061

[8] A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma [J].

Benson, Don M., Jr. ;

Hofmeister, Craig C. ;

Padmanabhan, Swaminathan ;

Suvannasankha, Attaya ;

Jagannath, Sundar ;

Abonour, Rafat ;

Bakan, Courtney ;

Andre, Pascale ;

Efebera, Yvonne ;

Tiollier, Jerome ;

Caligiuri, Michael A. ;

Farag, Sherif S. .

BLOOD, 2012, 120 (22) :4324-4333

[9] IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect [J].

Benson, Don M., Jr. ;

Bakan, Courtney E. ;

Zhang, Shuhong ;

Collins, Shauna M. ;

Liang, Jing ;

Srivastava, Shivani ;

Hofmeister, Craig C. ;

Efebera, Yvonne ;

Andre, Pascale ;

Romagne, Francois ;

Blery, Mathieu ;

Bonnafous, Cecile ;

Zhang, Jianying ;

Clever, David ;

Caligiuri, Michael A. ;

Farag, Sherif S. .

BLOOD, 2011, 118 (24) :6387-6391

[10] The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody [J].

Benson, Don M., Jr. ;

Bakan, Courtney E. ;

Mishra, Anjali ;

Hofmeister, Craig C. ;

Efebera, Yvonne ;

Becknell, Brian ;

Baiocchi, Robert A. ;

Zhang, Jianying ;

Yu, Jianhua ;

Smith, Megan K. ;

Greenfield, Carli N. ;

Porcu, Pierluigi ;

Devine, Steven M. ;

Rotem-Yehudar, Rinat ;

Lozanski, Gerard ;

Byrd, John C. ;

Caligiuri, Michael A. .

BLOOD, 2010, 116 (13) :2286-2294

← 1 2 3 4 5 6 7 8 9 10 →